HCA Healthcare, Inc. (HCA) — ESG & Values Scores

Environment story

HCA Healthcare discloses minimal environmental metrics and lacks a credible net-zero commitment. Scope 1, Scope 2, and Scope 3 emissions data are not disclosed in available filings. No verified renewable energy percentage or decarbonization targets are documented. The company operates 186 hospitals and numerous ancillary facilities generating significant medical waste and pharmaceutical disposal requirements subject to federal and state environmental regulations, yet no proactive emissions reduction initiatives or climate targets are evident. Absence of disclosed climate governance or ESG reporting frameworks suggests limited environmental prioritization relative to financial and operational risks. Environmental score reflects undisclosed emissions, missing net-zero target, lack of verified decarbonization infrastructure, and regulatory compliance posture rather than leadership.

Criticisms on file

Lack of disclosed Scope 1, 2, and 3 emissions data; no net-zero target or renewable energy commitments disclosed.
Source: HCA 10-K 2025; Proxy Statement 2026 — comprehensive search of filings reveals no climate or ESG metrics.
Medical waste and environmental compliance risks noted in 10-K risk factors without evidence of mitigation beyond regulatory adherence.
Source: HCA 10-K Item 1A Risk Factors, pg. 42-43: 'various international, federal, state and local statutes and ordinances regulating the discharge of materials into the environment.'

Disclosed initiatives

Environmental Compliance and Medical Waste Management

HCA operates under federal, state, and local environmental laws regulating discharge of materials, medical waste handling, pharmaceuticals, biological materials, and disposable medical instruments.

Regulatory compliance only; no evidence of proactive decarbonization or emissions reduction beyond legal requirements.

Social story

HCA Healthcare faces significant labor-market pressures and documented union activity concerns. The 10-K identifies nurses and healthcare professional shortages as a material operating risk, requiring wage increases and temporary staffing at elevated costs. The company acknowledges union organizing activity, collective bargaining negotiations, and past labor strikes as ongoing risks. CEO-to-median-worker pay ratio is not disclosed in proxy filings, preventing direct calculation but suggesting potential misalignment. Diversity metrics for executive and board leadership are not quantified in disclosed materials. The company provides uninsured discounts and charity care ($4.605 billion uncompensated care in 2025) but faces increasing collection challenges as uninsured populations grow due to policy changes. Supply-chain ethics for pharmaceutical and medical device sourcing are not detailed. Social score reflects undisclosed CEO pay ratio, union-related operational risks, lack of diversity transparency, and growing uninsured patient burden.

Criticisms on file

Labor shortages, union organizing activity, and past labor strikes acknowledged as material risks; ongoing negotiations with labor unions referenced.
Source: HCA 10-K Item 1A Risk Factors, pg. 35: 'Our results of operations may be adversely affected by competition for staffing, the shortage of experienced nurses and other health care professionals and labor union activity.'
CEO-to-median-worker pay ratio not disclosed; executive compensation structure not transparently reported relative to workforce pay.
Source: HCA Proxy Statement 2026 — 2025 Summary Compensation Table reports named executive officer compensation but no CEO-to-median-worker ratio calculation disclosed.
Uninsured patient burden growing due to policy changes; $4.605 billion uncompensated care and collection challenges increasing.
Source: HCA 10-K Item 1A Risk Factors, pg. 46-47: 'expiration of enhanced premium tax credits will adversely impact Exchange enrollment and increase the uninsured rate.'

Disclosed initiatives

Recruitment and Retention of Healthcare Personnel

HCA acknowledges need to increase wages and benefits to compete for nurses and medical support personnel; offers competitive employment terms and succession planning for management.

Reactive wage inflation response to labor market conditions; no evidence of progressive labor practices or union partnership models.
Uninsured and Charity Care

HCA provided $4.605 billion in uncompensated care in 2025; offers uninsured discounts and charity care for vulnerable populations including undocumented immigrants and Medicaid-eligible uninsured.

Material community benefit but reflects growing uninsured crisis rather than proactive social equity strategy; collection challenges increasing.
Workplace Safety and Compliance

10-K references compliance with workplace safety regulations and patient/workforce safety oversight, but limited detail disclosed.

Regulatory compliance framework; no quantified safety metrics or incident rates disclosed.

Governance story

HCA Healthcare maintains a governance structure with separated Chairman and CEO roles, 7 of 10 current directors identified as independent (70% independence), and board committees composed of independent directors. However, a stockholders' agreement grants the Frist family and original Sponsors ongoing rights to nominate two board members, creating a controlling-shareholder dynamic that limits full board independence. The company operates under a single-class share structure (one share, one vote) with no supermajority provisions, and maintains proxy access rights. Lobbying activities and political contributions are disclosed at the board level but specific annual lobbying expenditures targeting healthcare deregulation are not quantified in filings. The company faces no active dual-class voting structure but the Frist family stockholders' agreement effectively concentrates influence. No material antitrust, consumer-fraud, or significant regulatory proceedings disclosed in 2025 proxy/10-K filings. Governance score reflects strong board independence, robust committee structure, absence of supermajority voting, but reduced points for controlling stockholders' agreement limiting true independence and undisclosed lobbying-spend detail.

Criticisms on file

Frist family and original Sponsors retain stockholders' agreement with nomination rights for two board directors, limiting full board independence despite 70% formally independent directors.
Source: HCA Proxy Statement 2026, pg. 12: 'Amended and Restated Stockholders' Agreement...provides...for certain rights of the Frist Group to nominate two members of our Board of Directors.'
Lobbying activities and political contributions oversight delegated to Nominating and Corporate Governance Committee, but specific annual lobbying expenditures and lobbying targets (climate deregulation, consumer-protection rollbacks) not disclosed in filings.
Source: HCA Proxy Statement 2026, pg. 11: 'Nominating and Corporate Governance Committee: corporate governance, corporate responsibility and community interests, including political activities and lobbying'; annual lobbying spend not quantified.
Ongoing exposure to False Claims Act, Anti-kickback Statute, and Stark Law violations through qui tam whistleblower suits and government audits; no material resolved fines disclosed but systemic compliance risk acknowledged.
Source: HCA 10-K Item 1A Risk Factors, pg. 42-43: 'under the FCA, private parties have the right to bring qui tam, or whistleblower, suits against companies that submit false claims for payments.'

Disclosed initiatives

Board Independence and Committee Structure

Seven of ten current directors identified as independent; Audit and Compliance, Compensation, and Nominating and Corporate Governance Committees composed solely of independent directors. Chairman/CEO roles separated (Thomas F. Frist III as Chairman; Samuel N. Hazen as CEO).

Strong governance framework; independent board oversight of audit, compensation, and nomination functions.
Stockholder Rights and Proxy Access

No stockholder rights plan or poison pill; stockholders may call special meetings; proxy access available for stockholders holding 3%+ stock for three years; one-year director terms.

Robust stockholder engagement mechanisms and annual director accountability.
Risk Oversight and Corporate Responsibility

Board oversight of enterprise-wide risk management; Audit and Compliance Committee oversight of cybersecurity, data protection, AI, and information technology risks; Nominating and Corporate Governance Committee oversight of political activities and lobbying.

Documented governance committee structure for emerging risks including cybersecurity and AI; political-activity transparency required.
Executive Succession Planning and Compensation Governance

Compensation Committee oversees human capital management, workplace culture, and employee relations; succession planning acknowledged in 10-K.

Formal governance framework for talent management and executive transition.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of HCA Healthcare, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open HCA Healthcare, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)